Strategic Acquisition Clean Cells’ June 2026 acquisition of Stem Genomics expands its quality controls for stem cell therapy and adds the iCS-digital PSC platform, signaling an opportunity to cross-sell enhanced QC services and integrated cell therapy workflows to stem cell and regenerative medicine players.

Capacity Expansion The 2025 expansion to a 5,300 m² cGMP facility in Montaigu-Vendée significantly boosts manufacturing and testing capacity, creating possibilities to upsell larger clinical programs, accelerated timelines, and end‑to‑end biopharmaceutical QC and manufacturing solutions.

Geographic Growth Strategic presence in Western France with international footprint through Naobios collaboration positions Clean Cells to pursue EU and US biologics clients seeking scalable QC testing, process development, and virus-based product manufacturing support.

Biologics Focus As a GMP-licensed CDMO offering R&D, production and QC testing for biologics, Clean Cells is a natural partner for sponsors developing biologics, cell therapies, and viral vectors, presenting cross-sell opportunities for development to GMP production transitions.

Industry Collaboration Partnerships with Naobios and growth in biosciences events such as Bio Korea 2026 indicate a market-facing strategy to win collaborations, joint development projects, and multi‑site engagements with global biopharma players seeking integrated QC and manufacturing capabilities.